Intrust Bank NA Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Intrust Bank NA trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 1.4% during the 4th quarter, HoldingsChannel reports. The fund owned 14,367 shares of the company’s stock after selling 203 shares during the quarter. Eli Lilly and Company comprises 1.0% of Intrust Bank NA’s holdings, making the stock its 17th biggest position. Intrust Bank NA’s holdings in Eli Lilly and Company were worth $8,375,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Naviter Wealth LLC increased its position in Eli Lilly and Company by 9.6% in the fourth quarter. Naviter Wealth LLC now owns 3,650 shares of the company’s stock worth $2,128,000 after buying an additional 319 shares in the last quarter. Bluesphere Advisors LLC increased its position in Eli Lilly and Company by 98.5% in the fourth quarter. Bluesphere Advisors LLC now owns 1,209 shares of the company’s stock worth $705,000 after buying an additional 600 shares in the last quarter. Choreo LLC increased its position in Eli Lilly and Company by 35.3% in the fourth quarter. Choreo LLC now owns 8,643 shares of the company’s stock worth $5,038,000 after buying an additional 2,257 shares in the last quarter. McAdam LLC increased its position in Eli Lilly and Company by 5.6% in the fourth quarter. McAdam LLC now owns 1,590 shares of the company’s stock worth $927,000 after buying an additional 84 shares in the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. increased its position in Eli Lilly and Company by 0.8% in the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 7,282 shares of the company’s stock worth $4,245,000 after buying an additional 60 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $3.69 during midday trading on Monday, hitting $737.20. The company had a trading volume of 2,663,604 shares, compared to its average volume of 3,007,265. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market cap of $700.46 billion, a price-to-earnings ratio of 126.34, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The business’s 50-day simple moving average is $761.79 and its 200-day simple moving average is $667.10.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.09 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.